
Benzinga Pro data, Agile Therapeutics (NASDAQ:AGRX) reported Q4 sales of $1.51 million. Earnings fell to a loss of $23.36 million, resulting in a 39.26% decrease from last quarter. Agile Therapeutics collected $1.29 million in revenue during Q3, but reported earnings showed a $16.77 million loss.